Search Results - "Jernival, Tony"

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone by Boehrer, Simone, Beyne-Rauzy, Odile, Prebet, Thomas, Park, Sophie, Guerci, Agnès, Stamatoulas, Aspasia, Chaury, MP, Jernival, Tony, Sanhes, Laurence, Tertian, Gerard, Cheze, Stephane, Lim, Eng-Mong, Choufi, Bachra, Caillot, Denis, Wattel, E., Delaunay, Jacques, Legros, Laurence, Chermat, Fatiha, Isnard, Françoise, Cambier, N., Slama, Borhane, Roy, Lydia, Damaj, Gandhi, Raffoux, Emmanuel, Dreyfus, Francois, Récher, Christian, Vey, Norbert, Chevret, Sylvie, Fenaux, Pierre, Gardin, Claude

“…Abstract 1880 Red blood cell (RBC) cell transfusion dependency (TD) is an indicator of poor prognosis in IPSS low and int-1 (lower risk) MDS. In addition,…”
Get full text

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study by Gardin, Claude, Prébet, Thomas, Bouabdallah, Krimo, Caillot, Denis, Guerci, Agnès, Raffoux, Emmanuel, Marolleau, Jean Pierre, Pautas, Cecile, Banos, Anne, Himberlin, Chantal, Taksin, Anne-Laure, Pigneux, Arnaud, Thomas, Xavier, Jernival, Tony, Vey, Norbert, Dreyfus, Francois, Chevret, Sylvie, Dombret, Herve, Fenaux, Pierre

“…Abstract 844 intensive chemotherapy (IC) in AML post-MDS (here AML) or High Risk-MDS (here MDS) is associated with lower CR rate, shorter response duration and…”
Get full text

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study by Kelaidi, Charikleia, Beyne-Rauzy, Odile, Braun, Thorsten, Cougoul, Pierre, Ades, Lionel, Pillard, Fabien, Lamberto, Christine, Jernival, Tony, Mortera, Edith, Guerci, Agnes, Choufi, B., Stamatoullas, Aspasia, Slama, Borhane, De Renzis, Benoît, Ame, S., Ghandi, Damaj, Boyer, Françoise, Chaury, Marie-Pierre, Legros, Laurence, Cheze, Stéphane, Testu, Anna, Gyan, Emmanuel, Bene, Marie C, Rose, Christian, Dreyfus, Francois, Fenaux, Pierre

“…Abstract 3812 Poster Board III-748 Background. DAR is a hyperglycosylated erythroblastic stimulating agent (ESA) with prolonged half life. Previous studies…”
Get full text